Small Molecules

02 Feb 2021 Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
02 Feb 2021 PharmaMar presents new data on Zepzelca® (lurbinectedin) in combination with irinotecan at an oral session at (rescheduled) IASLC 2020
01 Feb 2021 Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa
01 Feb 2021 Bristol Myers Squibb Application for Zeposia® (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration
01 Feb 2021 Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia
30 Jan 2021 Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
30 Jan 2021 Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
30 Jan 2021 Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures
30 Jan 2021 Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
29 Jan 2021 Tagrisso extended disease-free survival regardless of prior adjuvant chemotherapy in early-stage EGFR-mutated lung cancer
29 Jan 2021 Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
29 Jan 2021 Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
28 Jan 2021 EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
28 Jan 2021 Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
28 Jan 2021 United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective
28 Jan 2021 Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
28 Jan 2021 Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema
28 Jan 2021 Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease
27 Jan 2021 Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)
27 Jan 2021 Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
26 Jan 2021 Qurient Enrolls First Patient in Q702 U.S. Phase 1 Study
26 Jan 2021 Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
25 Jan 2021 European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
25 Jan 2021 Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors
25 Jan 2021 Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up